HOME >> BIOLOGY >> NEWS
Macrochem acquires option to license pexiganan

WELLESLEY HILLS, Mass., July 10 /PRNewswire-FirstCall/ -- MacroChem Corporation (OTCBB: MACM - News) today announced that it has signed an exclusive option to acquire exclusive worldwide license rights for drug uses of pexiganan, a novel, small peptide anti-infective for topical treatment of patients with mild diabetic foot infection (DFI), from Genaera Corporation (Genaera).

"We believe this is a unique opportunity for MacroChem to broaden its product portfolio with a product that has already completed two Phase 3 clinical trials. It also fits our strategic focus and complements our lead product candidate, EcoNail(TM) for treatment of nail fungus currently in a fully enrolled Phase 2 trial and progressing on track with an interim assessment of clinical data later this year after all patients have been treated for twenty four weeks," said Robert J. DeLuccia, President and CEO of MacroChem.

Clinical trials with pexiganan previously conducted by Genaera include two Phase 3 trials submitted in a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in 1998. At that time, outstanding issues with CMC (Chemistry, Manufacturing and Controls) and an FDA request for one additional controlled trial precluded approval.

Mr. DeLuccia further noted, "We would be pleased to have pexiganan in our hands since we believe that, if approved, it would be welcomed by physicians and patients for the treatment of diabetic foot infection. In recent years, there have been many advances in the manufacturing of peptides, a better understanding of the treatment of diabetic foot infection, improvements in clinical trial design and execution, and more clarity concerning regulatory requirements for topical anti-infectives with the potential market being even more attractive than before."

He added, "There continues to be a very large and growing incidence of diabetes and, as a result, a growing number of diabetic foot infections in the
'"/>

Contact: Bill Douglass
bdouglass@investorrelationsgroup.com
212-825-3210
MacroChem
10-Jul-2007


Page: 1 2

Related biology news :

1. Biogen Idec acquires Brandeis spin-out
2. Wiley acquires publications from Carpe Diem Communications
3. Ossur hf. acquires the Gibaud Group in France
4. Springer acquires BioTribune Magazine and Biotribune.com
5. Stevens Davidson Laboratory acquires new research vessel
6. Accentia Biopharmaceuticals acquires exclusive license
7. Ossur acquires US orthotics company Royce Medical
8. Molecular Profiling Institute, Inc. acquires NanoBiomics, Inc.
9. European approval of HIV drug darunavir will provide a potent new option with Fuzeon
10. Fat stem cells being studied as option for breast reconstruction
11. Drug offers new options for leukemia patients

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/12/2018)... (PRWEB) , ... September 11, 2018 , ... ... coatings, is proud to introduce the new ChemXP™ line of high performance secondary ... The line was developed to provide Tennant Coatings’ elite certified installers with the ...
(Date:9/7/2018)... (PRWEB) , ... September 06, 2018 , ... ... Amedica Corporation (NASDAQ: AMDA) to purchase its commercial spine business, which includes its ... directly related to the spine that result from it. The deal will make ...
(Date:8/31/2018)... ... August 30, 2018 , ... ... Research. Jacklyn Novak, infrared materials engineer, LightPath Technologies. In the future, these names ... just celebrated her 100th birthday. Today, they are among 26 scientists whose work ...
Breaking Biology News(10 mins):
(Date:8/29/2018)... ... 28, 2018 , ... CEO and founder of VetStem Biopharma, ... on an allogeneic (donor derived) stem cell product for osteoarthritis in canines at ... September. He is also the organizer of Breakout Session 4: Practitioner Primer on ...
(Date:8/29/2018)... ... 2018 , ... USDM Life Sciences , the leading risk management, technological ... that Manu Vohra will deliver a presentation at the BoxWorks 2018 conference ... for GxP in 30 Days” , When: Thursday, August 30, 1:00-1:50 PM PT, Where: ...
(Date:8/26/2018)... ... August 24, 2018 , ... ExoCoBio ... exosomes dramatically relieves atopic dermatitis and inhibits a variety of inflammatory targets in ... paper, the symptoms of mice having severe atopic dermatitis were significantly improved after ...
(Date:8/23/2018)... , ... August 23, 2018 , ... Visikol ... Co-Founder Dr. Thomas Villani. Through support from advisors, mentors, the Rutgers Technology Transfer team ... , Visikol’s path from an idea to a successful biotech company has been a ...
Breaking Biology Technology:
Cached News: